{"podcast":{"title":"DOC Updates","slug":"doc-updates-200053","podcast_index_feed_id":200053,"rss_url":"https://diabetescoreupdate.libsyn.com/rss","website_url":"http://diabetescoreupdate.libsyn.com","image_url":"https://static.libsyn.com/p/assets/8/b/9/4/8b94720f00784a7316c3140a3186d450/DOCU_PodcastThumbnail_3000x3000-20260616-2cie7mvhpx.png","author":"American Diabetes Association","episode_count":100,"summary":"DOC Updates is a monthly podcast that presents and discusses the latest clinically relevant articles in the field of diabetes research and care, including the American Diabetes Association's three science and health journals – Diabetes, Diabetes Care, and Diabetes, Obesity, and Cardiometabolic CARE. Each episode is approximately 15 minutes long and presents 5-6 recently published articles from ADA journals and beyond. Intended for practicing physicians and health care professionals, DOC Updates discusses how the latest research and information published in journals of the American Diabetes Association and beyond are relevant to clinical practice and can be applied in a treatment setting. For more information about each of ADA's science and medical journals, please visit www.diabetesjournals.org. Presented by: Neil Skolnik, M.D. , Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health John J. Russell, M.D., Clinical Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Director, Family Medicine Residency…","last_synced_at":"2026-06-25T04:17:43.445630+00:00","page_url":"https://stenobird.com/podcast/doc-updates-200053"},"episode":{"title":"Associations between GLP-1 Receptor Agonists and Ischemic Optic Neuropathy, Tirzepetide vs. Dulaglutide or Semaglutide on major cardiovascular events in T2D, and more!","slug":"associations-between-glp-1-receptor-agonists-and-ischemic-optic-neuropathy-tirzepetide-vs-dulaglutide-or-semaglutide-on-major-cardiovascular-events-in-t2d-and-more","published_at":"2026-05-01T10:00:00+00:00","page_url":"https://stenobird.com/podcast/doc-updates-200053/associations-between-glp-1-receptor-agonists-and-ischemic-optic-neuropathy-tirzepetide-vs-dulaglutide-or-semaglutide-on-major-cardiovascular-events-in-t2d-and-more","show_page_url":"https://stenobird.com/podcast/doc-updates-200053","url":"https://diabetescoreupdate.libsyn.com/associations-between-glp-1-receptor-agonists-and-ischemic-optic-neuropathy-tirzepetide-vs-dulaglutide-or-semaglutide-on-major-cardiovascular-events-in-t2d-and-more","audio_url":"https://traffic.libsyn.com/secure/diabetescoreupdate/Diabetes_Core_Update_May_2026.mp3?dest-id=159994","summary":"Welcome to the latest episode (May 2026) of Diabetes Core Update , where every month Neil Skolnik, MD and John Russell, MD review the most important articles on diabetes, obesity, and cardiometabolic disease. This month, they discuss: Marston NA, Bohula EA, Bhatia AK, et al. \" Evolocumab to Reduce First Major Cardiovascular Events in Patients Without Known Significant Atherosclerosis and With Diabetes: Results From the VESALIUS-CV Trial .\" JAMA. 2026;335(16):1400–1407. doi:10.1001/jama.2026.3277 Lee YJ, Lee SJ, Kim JW, et al. \" Intensive LDL Cholesterol Targeting in Atherosclerotic Cardiovascular Disease .\" N Engl J Med 2026;394:1365-1375. doi:10.1056/NEJMoa2600283 Nissen SE, Wolski K, D'Alessio D, et al. \" Cardiorenal Outcomes With Tirzepatide Compared With Dulaglutide in Patients With Diabetes and Cardiovascular Disease: A Post Hoc Analysis of the SURPASS-CVOT Randomized Clinical Trial .\" JAMA Cardiol. Published online March 28, 2026. doi:10.1001/jamacardio.2026.0767 Moura FA, et al. \" Association Between GLP-1 Receptor Agonists and Ischemic Optic Neuropathy: A Meta-analysis .\" Diabetes Care. 2026;49(5):724–729. doi.org/10.2337/dc25-1238 Ostrominski JW, Ortega-Montiel J, et al. \" Comparative Effectiveness of Tirzepatide Versus Dulaglutide or Semaglutide on Major Cardiovascular Events in Type 2 Diabetes and Cardiovascular Disease: Insights From Two Target-Trial Emulations .\" Diabetes Care. 2026;49(5):808–817 doi.org/10.2337/dc25-3063 Nicole Napoli, \" Shingles Vaccine Drastically Cuts Risk of Serious Cardiac Events .\" The American College of Cardiology. March 17, 2026 https://www.acc.org/About-ACC/Press-Releases/2026/03/16/19/33/Shingles-Vaccine-Drastically-Cuts-Risk-of-Serious-Cardiac-Events For information about the American Diabetes Association's scholarly journals,…","meta_description":"Welcome to the latest episode (May 2026) of Diabetes Core Update , where every month Neil Skolnik, MD and John Russell, MD review the most important artic…","key_points":[],"chapters":[],"topics":[],"duration_seconds":2219,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/doc-updates-200053/episodes/associations-between-glp-1-receptor-agonists-and-ischemic-optic-neuropathy-tirzepetide-vs-dulaglutide-or-semaglutide-on-major-cardiovascular-events-in-t2d-and-more/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/doc-updates-200053/associations-between-glp-1-receptor-agonists-and-ischemic-optic-neuropathy-tirzepetide-vs-dulaglutide-or-semaglutide-on-major-cardiovascular-events-in-t2d-and-more.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]}}